310 related articles for article (PubMed ID: 8978799)
1. [Etoposide (VP-16) in gynecologic malignancy].
Kanazawa K; Moromizato H
Gan To Kagaku Ryoho; 1996 Dec; 23(14):1925-8. PubMed ID: 8978799
[TBL] [Abstract][Full Text] [Related]
2. Methotrexate monotherapy for high-risk gestational trophoblastic neoplasia after therapy with etoposide, methotrexate, and dactinomycin: a case report.
Taran A; Ignatov A; Smith B; Bischoff J; Costa SD
Am J Obstet Gynecol; 2008 Nov; 199(5):e6-8. PubMed ID: 18984073
[TBL] [Abstract][Full Text] [Related]
3. High-risk metastatic gestational trophoblastic disease. A new dose-intensive, multiagent chemotherapeutic regimen.
Surwit EA; Childers JM
J Reprod Med; 1991 Jan; 36(1):45-8. PubMed ID: 1848900
[TBL] [Abstract][Full Text] [Related]
4. Alternating weekly chemotherapy with etoposide-methotrexate-dactinomycin/cyclophosphamide-vincristine for high-risk gestational trophoblastic disease.
Soper JT; Evans AC; Clarke-Pearson DL; Berchuck A; Rodriguez G; Hammond CB
Obstet Gynecol; 1994 Jan; 83(1):113-7. PubMed ID: 8272290
[TBL] [Abstract][Full Text] [Related]
5. Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors.
Newlands ES; Mulholland PJ; Holden L; Seckl MJ; Rustin GJ
J Clin Oncol; 2000 Feb; 18(4):854-9. PubMed ID: 10673528
[TBL] [Abstract][Full Text] [Related]
6. Gestational trophoblastic disease.
Hammond CB; Olt GJ
Curr Ther Endocrinol Metab; 1994; 5():567-70. PubMed ID: 7704794
[No Abstract] [Full Text] [Related]
7. Plasma methotrexate levels in patients receiving etoposide, methotrexate, actinomycin, cyclophosphamide, and vincristine (EMA-CO) chemotherapy for trophoblastic neoplasia.
Kohorn EI
Gynecol Oncol; 1993 Sep; 50(3):300-4. PubMed ID: 8406191
[TBL] [Abstract][Full Text] [Related]
8. Etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine for the treatment of metastatic, high-risk gestational trophoblastic disease.
Schink JC; Singh DK; Rademaker AW; Miller DS; Lurain JR
Obstet Gynecol; 1992 Nov; 80(5):817-20. PubMed ID: 1328977
[TBL] [Abstract][Full Text] [Related]
9. [Methotrexate in gynecologic oncology].
Isonishi S; Terashima Y
Gan To Kagaku Ryoho; 1996 Dec; 23(14):1896-900. PubMed ID: 8978793
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy of gestational trophoblastic disease.
Omura GA
J Clin Oncol; 2000 May; 18(10):2187. PubMed ID: 10811687
[No Abstract] [Full Text] [Related]
11. Poor-prognosis gestational trophoblastic disease: an update.
Surwit EA; Alberts DS; Christian CD; Graham VE
Obstet Gynecol; 1984 Jul; 64(1):21-6. PubMed ID: 6204257
[TBL] [Abstract][Full Text] [Related]
12. Placental site trophoblastic tumor: an overview.
Bonazzi C; Urso M; Dell'Anna T; Sacco S; Buda A; Cantú MG
J Reprod Med; 2004 Aug; 49(8):585-8. PubMed ID: 15457847
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy-resistant gestational trophoblastic neoplasia treated successfully with cisplatin, etoposide, and bleomycin.
Willemse PH; Aalders JG; Bouma J; Sleijfer DT
Obstet Gynecol; 1988 Mar; 71(3 Pt 2):438-40. PubMed ID: 2450325
[TBL] [Abstract][Full Text] [Related]
14. Comparison of chemotherapies with methotrexate, VP-16 and actinomycin-D in low-risk gestational trophoblastic disease. Remission rates and drug toxicities.
Matsui H; Iitsuka Y; Seki K; Sekiya S
Gynecol Obstet Invest; 1998; 46(1):5-8. PubMed ID: 9692333
[TBL] [Abstract][Full Text] [Related]
15. A novel strategy using G-CSF to support EMA/CO for high-risk gestational trophoblastic disease.
Hartenbach EM; Saltzman AK; Carter JR; Twiggs LB
Gynecol Oncol; 1995 Jan; 56(1):105-8. PubMed ID: 7529741
[TBL] [Abstract][Full Text] [Related]
16. Management of high-risk gestational trophoblastic disease.
Surwit EA
J Reprod Med; 1987 Sep; 32(9):657-62. PubMed ID: 2822919
[TBL] [Abstract][Full Text] [Related]
17. Management of high-risk gestational trophoblastic disease.
Lurain JR
J Reprod Med; 1998 Jan; 43(1):44-52. PubMed ID: 9475149
[TBL] [Abstract][Full Text] [Related]
18. Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high risk disease and EA (etoposide and dactinomycin) as second-line therapy for low risk disease.
Dobson LS; Lorigan PC; Coleman RE; Hancock BW
Br J Cancer; 2000 May; 82(9):1547-52. PubMed ID: 10789722
[TBL] [Abstract][Full Text] [Related]
19. The management of gestational trophoblastic tumors with etoposide, methotrexate, and actinomycin D.
Soto-Wright V; Goldstein DP; Bernstein MR; Berkowitz RS
Gynecol Oncol; 1997 Jan; 64(1):156-9. PubMed ID: 8995566
[TBL] [Abstract][Full Text] [Related]
20. Management of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine chemotherapy.
Cyriac S; Rajendranath R; Sridevi V; Sagar TG
J Reprod Med; 2011; 56(5-6):219-23. PubMed ID: 21682117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
